Antiviral combination therapies are the medicines that are made by combining more than two drugs for the treatment of viral infections and chronic diseases such as HIV, hepatitis C, hepatitis B, etc. This treatment helps stop the virus from mutating and multiplying, thus, restricting the growth and helping in faster recovery process.
Increasing research & development activities and funding from the investors is one of the key factors supporting the growth of the global antiviral combination therapies market in forthcoming years. Also, increased demand for medicine to treat chronic ailments like HIV and the need to develop drugs and vaccines for COVID-19 is also fueling the market demand.
The key players are also focusing to rework on their strategies and take business-oriented activities on priority like mergers and acquisitions, joint ventures, product launches, collaborations, etc. This is foreseen to provide momentum to the existing market demand for antiviral combination therapies.
Organizations are taking critical steps in the antiviral combination treatment market by expanding their ways to handle COVID-19. To develop COVID-19 combination therapies, the Indian Institute of Chemical Technology (IICT) has collaborated with the Indian auxiliary of the global drug organization, Mylan. Healthcare firms are accelerating their efforts to join forces with the clinics and hospitals for combination treatment preliminaries. The combination of antiviral medications with anti-toxins has been appeared to have the positive potential for patients to decrease the symptoms of coronavirus.
The global antiviral combination therapies market is broadly classified into drug combination, indication, distribution channel, and region. The drug combination segment is divided into Integrase Inhibitor/NRTI, NRTI/Protease Inhibitor, NTRI/NNRTI, and others. In terms of indication segment, the market is classified into Hepatitis, HIV, and others. On the basis of distribution channel, the market is categorized into retail pharmacies, hospital pharmacies, and others.
The global antiviral combination therapies market is foreseen to be led by North America within the forecast period owing to rising cases of hepatitis and HIV-like diseases among the people. Moreover, the rising sales of generic medicines for HIV treatment are also contributing to the market revenue. Additionally, Asia Pacific is also estimated to register significant growth in the coming years. This is attributed to increasing awareness about the protection of drugs by making them patent. Moreover, the region is also witnessing a surge in the number of cases of chronic diseases in the past few years.
The global antiviral combination therapies market is well occupied by the leading players such as Bristol-Myers Squibb Company, Gilead Sciences, Inc., Mylan N.V., GlaxoSmithKline plc, Janssen Global Services, LLC, Celltrion, Inc., AbbVie, Inc., Merck & Co., Inc., Cipla, Inc., F. Hoffmann-La Roche Ltd., and others.
Recently, one of the major firms, Boehringer Ingelheim discussed its plan to invest around US$65 mn in Lyon Porte-des-Alpes, France, to meet the rising demand for avian vaccines around the world.